Welcome to Invero Health
|
Optimize Your Commercial Potential
|
First and Second Opinions |
Market Research |
|
Adding seasoned executives to collaborate on key issues in a business or launch plan can lead to increased confidence which almost always results in faster and more efficient implementation.
Building an OrganizationInvero Health staff have senior level experience building and running business units, acquiring businesses, and starting up from scratch a US marketing subsidiary for a European company.
|
No market research is perfect and adding more doesn't necessarily improve the result...sometimes more just obfuscates the key issues by creating more data but less actionable information. Efficient market research travels a hierarchy of sequential decisions which provide the infrastructure of a business plan.
Experience X FourExperience is the best teacher. Having led various product launches and relaunches, we have explored many options and built networks of expert advisers who can be brought to bear on just about any issue.
|
Why Invero Health?
Invero Health, LLC is a pharmaceutical consulting group focused on the US market. We specialize in advising and building new marketing organizations, including new legal entities where necessary. Our expertise comes from our three founding partners, each with more than 35 years’ experience in pharmaceuticals, and their extensive network of experts and partners.
Our team’s know-how and skills range from general management, marketing, sales, and market access, including HEOR, to medical affairs, clinical development, in-licensing and life cycle management – including all related specialties in regulatory affairs, business development, market research, operations, training and development as well as product supply.
All partners and management have extensive experience managing and developing brands and franchises in specialty pharmaceuticals including in oncology, neurology, cardiology, urology, women’s health, hospital products and diagnostic imaging.
Invero Health provides complete, end to end, commercial support to pharmaceutical and biotech companies, either building the organization from the ground up or providing support for companies with an established footprint in the US. We can help with all commercial activities, including all of the critical commercial input and direction into your clinical and regulatory plans, for any specialty product from the pre-clinical development phase to post-marketing status.
Whether a complete Go-to-Market plan is required or if there’s a specific need to concentrate on one particular area in the plan, Invero Health has the team that can put together the plan of action necessary to successfully launch or re-launch your brand. Our confidence in this statement comes from the fact that our entire team is made up of pharmaceutical executives, directors and managers. Collectively we have experienced every aspect of the product life cycle for more than 35 products and we’ve managed the market access, sales, marketing, product supply, distribution, medical and regulatory affairs for multi-billion dollar products and/or divisions including Sales teams between 100 and 1,000 sales consultants (both office and hospital-based), medical affairs field teams (between 12 and 50 field-based medical scientific liaisons and nursing support) the entire market access continuum including specialty account management (managed care, state & federal accounts, GPO’s, hospital IDN’s), reimbursement specialists, contracting, wholesaler and specialty distribution.
Who We Are
Douglas Stefanelli – Ken Liss – Robert Milos - Matt Napoletano
All four partners have extensive Pharmaceutical experience. Each has worked for Major Pharmaceutical and Specialty Pharmaceutical companies over their 35+ years in the Industry, holding various C-Suite positions such as CEO. president, vice president, CCO, COO, CFO, and General Manager at international Pharma companies including Schering AG and Bayer Healthcare.
Our team’s know-how and skills range from general management, marketing, sales, and market access, including HEOR, to medical affairs, clinical development, in-licensing and life cycle management – including all related specialties in regulatory affairs, business development, market research, operations, training and development as well as product supply.
All partners and management have extensive experience managing and developing brands and franchises in specialty pharmaceuticals including in oncology, neurology, cardiology, urology, women’s health, hospital products and diagnostic imaging.
Invero Health provides complete, end to end, commercial support to pharmaceutical and biotech companies, either building the organization from the ground up or providing support for companies with an established footprint in the US. We can help with all commercial activities, including all of the critical commercial input and direction into your clinical and regulatory plans, for any specialty product from the pre-clinical development phase to post-marketing status.
Whether a complete Go-to-Market plan is required or if there’s a specific need to concentrate on one particular area in the plan, Invero Health has the team that can put together the plan of action necessary to successfully launch or re-launch your brand. Our confidence in this statement comes from the fact that our entire team is made up of pharmaceutical executives, directors and managers. Collectively we have experienced every aspect of the product life cycle for more than 35 products and we’ve managed the market access, sales, marketing, product supply, distribution, medical and regulatory affairs for multi-billion dollar products and/or divisions including Sales teams between 100 and 1,000 sales consultants (both office and hospital-based), medical affairs field teams (between 12 and 50 field-based medical scientific liaisons and nursing support) the entire market access continuum including specialty account management (managed care, state & federal accounts, GPO’s, hospital IDN’s), reimbursement specialists, contracting, wholesaler and specialty distribution.
Who We Are
Douglas Stefanelli – Ken Liss – Robert Milos - Matt Napoletano
All four partners have extensive Pharmaceutical experience. Each has worked for Major Pharmaceutical and Specialty Pharmaceutical companies over their 35+ years in the Industry, holding various C-Suite positions such as CEO. president, vice president, CCO, COO, CFO, and General Manager at international Pharma companies including Schering AG and Bayer Healthcare.
Major Projects Completed...
Building new legal entities
Invero Health partners founded Averitas Pharma, LLC. Averitas is a highly-focused specialty pharmaceutical company that developed a unique business model to market a product called Qutenza, a non-opioid pain product. Qutenza was originally approved by the FDA in 2009 and although it had achieved significant marketing success in Europe, market penetration in the US eluded both prior attempts by prior owners. Averitas and all of its IP and business plans regarding Qutenza was subsequently acquired by Grünenthal GmbH, a mid-sized European pharmaceutical company.
Subsequent to the sale of Averitas, the partners were hired by Grunenthal to continue building a US commercial organization to market Qutenza as a specialty pharmaceutical through Grunenthal's now wholly-owned Averitas Pharma subsidiary. This involved selecting experienced partners and building an organization to manage...
New Product/NCE – Early Development
Your expert scientists have created a potentially ground breaking NCE in a specialty therapeutic area.
Your clinical and scientific teams are experts and focused on the synthesis of product and mechanisms of action.
You’re working on getting your IND submitted in order to get the product into humans.
Here’s why you shouldn’t move ahead without futurescaping the opportunity...
All too often, clinical trial design does not receive careful analysis of a likely future market place, including existing and possible new competitors, optimal dosage form identification, likely generic intrusion into the market and possible pricing impact, significant barriers to entry and issues arising from product administration to physician preferences, both clinically and economically.
Cash is often a major concern in new entities and spending needs to be prioritized toward critical activities that protect the existing cash and the ability to raise additional funds. Survival is the priority. Eliminating non-critical activities can be difficult because they may be good ideas in themselves, but when the future is uncertain, outsourcing is preferable to building infrastructure.
Invero partners have led the planning and execution of clinical development plans from early stage to label expansion projects at Berlex Labs (Bayer), Cephalon, Insys, Averitas Pharma, and Neuroprotexeon.
Pre-Launch, Post Launch, and Re-launch assessments
Getting it right the first time? Expanding a successful launch? Bringing new data and clinical insights into play?
Getting the most return on effort requires timely action by the entire team…building sales enthusiasm, integrating marketing insights, coordinating organizational capabilities. When everyone isn’t marching to the same beat, inefficiencies take money off the table.
We can come in and do it but a staff is often already in place to do that or should be. They will make up the team to be the company's commercial core. The thing is, the amount of work can outstrip the time required to plan it, confirm it, integrate feedback, and get buy in from key players. Shortcuts then turn into office politics and the inefficiencies start to build.
Invero Health can help you by acting as your Commercial Team. Our Founders have more than 90 years combined experience in the Pharmaceutical Industry and have prepared dozens of products for market entry. We will sit with your Management and Clinical teams to determine the best, and most realistic forecast for your NCE. We’ll help to guide the clinical trial design through our understanding of the market place and the practice of medicine within the products specialty area. Determine if adding Health Economics Outcomes are necessary. We’ll bring together decision makers within the value chain to help determine product profile, positioning and optimal price.
Our know-how and skills range from Marketing, Sales, and Market Access, to Clinical Development, In-licensing and Life Cycle Management – including all related specialties in clinical/medical and regulatory affairs, business development, market research, operations, training and development as well as product supply.
All Partners and Management have extensive experience managing and developing brands and franchises in Specialty Pharmaceuticals. Therapeutic areas include Oncology, Neurology, Cardiology, Urology, Women’s Health, Hospital Products and Diagnostic Imaging. Invero Health is dedicated to helping bring world class therapeutic and imaging agents to the U.S. market through our extensive expertise and commitment to our partners in the Pharmaceutical and Biotech industries.
Invero Health partners founded Averitas Pharma, LLC. Averitas is a highly-focused specialty pharmaceutical company that developed a unique business model to market a product called Qutenza, a non-opioid pain product. Qutenza was originally approved by the FDA in 2009 and although it had achieved significant marketing success in Europe, market penetration in the US eluded both prior attempts by prior owners. Averitas and all of its IP and business plans regarding Qutenza was subsequently acquired by Grünenthal GmbH, a mid-sized European pharmaceutical company.
Subsequent to the sale of Averitas, the partners were hired by Grunenthal to continue building a US commercial organization to market Qutenza as a specialty pharmaceutical through Grunenthal's now wholly-owned Averitas Pharma subsidiary. This involved selecting experienced partners and building an organization to manage...
- A Specialty Pharmacy Hub and Distribution Network
- Federal and State licensing
- CMO's and Importation
- Regulatory Affairs
- Medical Affairs
- Pharmaco-vigilance
- Compliance
- Promotional Agencies
- Contract Sales Organizations
New Product/NCE – Early Development
Your expert scientists have created a potentially ground breaking NCE in a specialty therapeutic area.
Your clinical and scientific teams are experts and focused on the synthesis of product and mechanisms of action.
You’re working on getting your IND submitted in order to get the product into humans.
Here’s why you shouldn’t move ahead without futurescaping the opportunity...
All too often, clinical trial design does not receive careful analysis of a likely future market place, including existing and possible new competitors, optimal dosage form identification, likely generic intrusion into the market and possible pricing impact, significant barriers to entry and issues arising from product administration to physician preferences, both clinically and economically.
Cash is often a major concern in new entities and spending needs to be prioritized toward critical activities that protect the existing cash and the ability to raise additional funds. Survival is the priority. Eliminating non-critical activities can be difficult because they may be good ideas in themselves, but when the future is uncertain, outsourcing is preferable to building infrastructure.
Invero partners have led the planning and execution of clinical development plans from early stage to label expansion projects at Berlex Labs (Bayer), Cephalon, Insys, Averitas Pharma, and Neuroprotexeon.
Pre-Launch, Post Launch, and Re-launch assessments
Getting it right the first time? Expanding a successful launch? Bringing new data and clinical insights into play?
Getting the most return on effort requires timely action by the entire team…building sales enthusiasm, integrating marketing insights, coordinating organizational capabilities. When everyone isn’t marching to the same beat, inefficiencies take money off the table.
We can come in and do it but a staff is often already in place to do that or should be. They will make up the team to be the company's commercial core. The thing is, the amount of work can outstrip the time required to plan it, confirm it, integrate feedback, and get buy in from key players. Shortcuts then turn into office politics and the inefficiencies start to build.
Invero Health can help you by acting as your Commercial Team. Our Founders have more than 90 years combined experience in the Pharmaceutical Industry and have prepared dozens of products for market entry. We will sit with your Management and Clinical teams to determine the best, and most realistic forecast for your NCE. We’ll help to guide the clinical trial design through our understanding of the market place and the practice of medicine within the products specialty area. Determine if adding Health Economics Outcomes are necessary. We’ll bring together decision makers within the value chain to help determine product profile, positioning and optimal price.
Our know-how and skills range from Marketing, Sales, and Market Access, to Clinical Development, In-licensing and Life Cycle Management – including all related specialties in clinical/medical and regulatory affairs, business development, market research, operations, training and development as well as product supply.
All Partners and Management have extensive experience managing and developing brands and franchises in Specialty Pharmaceuticals. Therapeutic areas include Oncology, Neurology, Cardiology, Urology, Women’s Health, Hospital Products and Diagnostic Imaging. Invero Health is dedicated to helping bring world class therapeutic and imaging agents to the U.S. market through our extensive expertise and commitment to our partners in the Pharmaceutical and Biotech industries.